Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
December 21, 2018
Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference
December 17, 2018
Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields
December 6, 2018
Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival
November 14, 2018
Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China
November 13, 2018
Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology
November 7, 2018
Novocure and Zai Lab to Host Investor Event
October 25, 2018
Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update
October 24, 2018
Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors
October 23, 2018
Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma
October 22, 2018
Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields
October 18, 2018
Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®
October 4, 2018
Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018
October 1, 2018
Novocure to Report Third Quarter 2018 Financial Results
September 25, 2018
Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer
September 12, 2018
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
September 5, 2018
Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control
August 15, 2018
Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer
August 3, 2018
Novocure to Present at Two Upcoming Investor Conferences
August 2, 2018
Novocure Announces Addition to Its Board of Directors
July 31, 2018
Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer
July 26, 2018
Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update
July 19, 2018
Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting
July 17, 2018
Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society
July 2, 2018
Novocure Appoints Pritesh Shah as Chief Commercial Officer
July 2, 2018
Novocure to Report Second Quarter 2018 Financial Results
June 4, 2018
Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018
May 31, 2018
Novocure Announces Changes to Its Board of Directors
April 26, 2018
Novocure Reports First Quarter 2018 Financial Results and Provides Company Update
April 17, 2018
Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
April 13, 2018
Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting
April 3, 2018
Novocure to Report First Quarter 2018 Financial Results
March 20, 2018
NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
March 15, 2018
Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018
February 22, 2018
Novocure Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Company Update
February 7, 2018
Novocure Secures New $150 Million Non-Dilutive Term Loan Financing
February 1, 2018
JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients
January 9, 2018
Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue